{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T14:02:18Z","timestamp":1780322538807,"version":"3.54.1"},"reference-count":60,"publisher":"American Society of Hematology","issue":"7","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,4,14]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Protease activated receptor 1 (PAR1) is expressed by numerous cell types, including endothelial cells. Thrombin cleaves PAR1 at Arg41 and activates proinflammatory and barrier disruptive signaling. Alternatively, PAR1 is cleaved at Arg46 by activated protein C (APC) that is bound to endothelial protein C receptor (ECPR), which induces anti-inflammatory and barrier protective signaling. In sickle cell disease (SCD), we showed that thrombin-PAR1 signaling contributes to vascular stasis and, more recently, that PAR1-R41\u2013biased signaling enhances inflammation, whereas PAR1-R46 signaling reduces thrombo-inflammation. We hypothesized that ECPR-PAR1-R46\u2013biased signaling protects sickle mice from thrombo-inflammation. To test this hypothesis, Townes sickle mice were treated with parmodulin (parmodulin 2 [PM2, aka ML161] or NRD-21) to promote protective, anti-inflammatory PAR1-biased signaling. We found that PM2 significantly attenuated thrombin generation, inflammation, and endothelial activation and protected sickle mice from a model of lethal acute chest syndrome. These results suggest that using PM2 to block thrombin-PAR1 signaling while inducing APC-like signaling can promote cytoprotective, anti-inflammatory effects in mouse models of SCD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025017522","type":"journal-article","created":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T17:53:16Z","timestamp":1770141196000},"page":"2351-2362","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":2,"title":["Targeting PAR1 biased signaling with parmodulin reduces thromboinflammation and acute lung injury in sickle cell disease"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9765-6895","authenticated-orcid":false,"given":"Nirupama","family":"Ramadas","sequence":"first","affiliation":[{"name":"1Blood Research Center, The University of North Carolina at Chapel Hill, Chapel Hill, NC"},{"name":"2Department of Pathology and Laboratory Medicine, The University of North Carolina at Chapel Hill, Chapel Hill, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0411-0026","authenticated-orcid":false,"given":"Kailyn","family":"Lowder","sequence":"additional","affiliation":[{"name":"1Blood Research Center, The University of North Carolina at Chapel Hill, Chapel Hill, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Dutton","sequence":"additional","affiliation":[{"name":"1Blood Research Center, The University of North Carolina at Chapel Hill, Chapel Hill, NC"},{"name":"2Department of Pathology and Laboratory Medicine, The University of North Carolina at Chapel Hill, Chapel Hill, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-4204-1889","authenticated-orcid":false,"given":"Rebecca Claire","family":"Kazen","sequence":"additional","affiliation":[{"name":"2Department of Pathology and Laboratory Medicine, The University of North Carolina at Chapel Hill, Chapel Hill, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8870-4675","authenticated-orcid":false,"given":"Rani","family":"Sellers","sequence":"additional","affiliation":[{"name":"2Department of Pathology and Laboratory Medicine, The University of North Carolina at Chapel Hill, Chapel Hill, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-5786-295X","authenticated-orcid":false,"given":"Jacob T.","family":"DeRousse","sequence":"additional","affiliation":[{"name":"3Function Therapeutics, Inc, Milwaukee, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4092-5636","authenticated-orcid":false,"given":"Christopher","family":"Dockendorff","sequence":"additional","affiliation":[{"name":"3Function Therapeutics, Inc, Milwaukee, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5529-7847","authenticated-orcid":false,"given":"Erica Marie","family":"Sparkenbaugh","sequence":"additional","affiliation":[{"name":"1Blood Research Center, The University of North Carolina at Chapel Hill, Chapel Hill, NC"},{"name":"2Department of Pathology and Laboratory Medicine, The University of North Carolina at Chapel Hill, Chapel Hill, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,3,31]]},"reference":[{"issue":"8","key":"2026041408013062700_bib1","doi-asserted-by":"crossref","first-page":"e585","DOI":"10.1016\/S2352-3026(23)00118-7","article-title":"Global, regional, and national prevalence and mortality burden of sickle cell disease, 2000-2021: a systematic analysis from the Global Burden of Disease Study 2021","volume":"10","author":"GBD 2021 Sickle Cell Disease Collaborators","year":"2023","journal-title":"Lancet Haematol"},{"key":"2026041408013062700_bib2","doi-asserted-by":"crossref","first-page":"18010","DOI":"10.1038\/nrdp.2018.10","article-title":"Sickle cell disease","volume":"4","author":"Kato","year":"2018","journal-title":"Nat Rev Primer"},{"issue":"4","key":"2026041408013062700_bib3","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.blre.2015.12.003","article-title":"Coagulation abnormalities of sickle cell disease: relationship with clinical outcomes and the effect of disease modifying therapies","volume":"30","author":"Noubouossie","year":"2016","journal-title":"Blood Rev"},{"issue":"2-3","key":"2026041408013062700_bib4","doi-asserted-by":"crossref","first-page":"301","DOI":"10.3233\/CH-189013","article-title":"Hypercoagulable state in sickle cell disease","volume":"68","author":"Faes","year":"2018","journal-title":"Clin Hemorheol Microcirc"},{"issue":"7","key":"2026041408013062700_bib5","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1111\/jth.13717","article-title":"Prothrombotic aspects of sickle cell disease","volume":"15","author":"Sparkenbaugh","year":"2017","journal-title":"J Thromb Haemost"},{"issue":"15","key":"2026041408013062700_bib6","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1182\/blood-2015-01-625707","article-title":"Genetic diminution of circulating prothrombin ameliorates multiorgan pathologies in sickle cell disease mice","volume":"126","author":"Arumugam","year":"2015","journal-title":"Blood"},{"issue":"17","key":"2026041408013062700_bib7","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1182\/blood-2018-03-822593","article-title":"How I diagnose and treat venous thromboembolism in sickle cell disease","volume":"132","author":"Shet","year":"2018","journal-title":"Blood"},{"key":"2026041408013062700_bib8","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.thromres.2020.08.004","article-title":"The domino effect triggered by the tethered ligand of the protease activated receptors","volume":"196","author":"Han","year":"2020","journal-title":"Thromb Res"},{"issue":"1","key":"2026041408013062700_bib9","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/jth.14643","article-title":"Molecular basis of protease-activated receptor 1 signaling diversity","volume":"18","author":"Willis Fox","year":"2020","journal-title":"J Thromb Haemost"},{"issue":"8","key":"2026041408013062700_bib10","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1111\/j.1538-7836.2005.01377.x","article-title":"Protease-activated receptors in hemostasis, thrombosis and vascular biology","volume":"3","author":"Coughlin","year":"2005","journal-title":"J Thromb Haemost"},{"issue":"6801","key":"2026041408013062700_bib11","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1038\/35025229","article-title":"Thrombin signalling and protease-activated receptors","volume":"407","author":"Coughlin","year":"2000","journal-title":"Nature"},{"issue":"6","key":"2026041408013062700_bib12","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/0092-8674(91)90261-V","article-title":"Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation","volume":"64","author":"Vu","year":"1991","journal-title":"Cell"},{"issue":"1-2","key":"2026041408013062700_bib13","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/0014-5793(91)81017-3","article-title":"cDNA cloning and expression of a hamster alpha-thrombin receptor coupled to Ca2+ mobilization","volume":"288","author":"Rasmussen","year":"1991","journal-title":"FEBS Lett"},{"issue":"22","key":"2026041408013062700_bib14","first-page":"2675","article-title":"Targeting biased signaling by PAR1: function and molecular mechanism of parmodulins","volume":"141","author":"K\u00fcnze","year":"2023","journal-title":"Blood"},{"issue":"8","key":"2026041408013062700_bib15","doi-asserted-by":"crossref","first-page":"3161","DOI":"10.1182\/blood-2006-09-003004","article-title":"The cytoprotective protein C pathway","volume":"109","author":"Mosnier","year":"2007","journal-title":"Blood"},{"issue":"19","key":"2026041408013062700_bib16","doi-asserted-by":"crossref","first-page":"2898","DOI":"10.1182\/blood-2015-02-355974","article-title":"Activated protein C: biased for translation","volume":"125","author":"Griffin","year":"2015","journal-title":"Blood"},{"issue":"50","key":"2026041408013062700_bib17","doi-asserted-by":"crossref","first-page":"E1372","DOI":"10.1073\/pnas.1112482108","article-title":"Activated protein C promotes protease-activated receptor-1 cytoprotective signaling through \u03b2-arrestin and dishevelled-2 scaffolds","volume":"108","author":"Soh","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8","key":"2026041408013062700_bib18","doi-asserted-by":"crossref","first-page":"3178","DOI":"10.1182\/blood-2004-10-3985","article-title":"Endothelial barrier protection by activated protein C through PAR1-dependent sphingosine 1-phosphate receptor-1 crossactivation","volume":"105","author":"Feistritzer","year":"2005","journal-title":"Blood"},{"issue":"49","key":"2026041408013062700_bib34","doi-asserted-by":"crossref","first-page":"e2106623118","DOI":"10.1073\/pnas.2106623118","article-title":"aPC\/PAR1 confers endothelial anti-apoptotic activity via a discrete, \u03b2-arrestin-2-mediated SphK1-S1PR1-Akt signaling axis","volume":"118","author":"Molinar-Inglis","year":"2021","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"20","key":"2026041408013062700_bib19","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1182\/blood.2019003543","article-title":"Thrombin activation of PAR-1 contributes to microvascular stasis in mouse models of sickle cell disease","volume":"135","author":"Sparkenbaugh","year":"2020","journal-title":"Blood"},{"issue":"11","key":"2026041408013062700_bib20","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1182\/blood-2017-10-810895","article-title":"PAR1 biased signaling is required for activated protein C in vivo benefits in sepsis and stroke","volume":"131","author":"Sinha","year":"2018","journal-title":"Blood"},{"issue":"12","key":"2026041408013062700_bib21","doi-asserted-by":"crossref","first-page":"3272","DOI":"10.1182\/bloodadvances.2023011907","article-title":"Biased agonism of protease-activated receptor-1 regulates thromboinflammation in murine sickle cell disease","volume":"8","author":"Ramadas","year":"2024","journal-title":"Blood Adv"},{"issue":"1","key":"2026041408013062700_bib22","doi-asserted-by":"crossref","first-page":"5062","DOI":"10.1038\/s41467-022-32477-9","article-title":"Reversal of the renal hyperglycemic memory in diabetic kidney disease by targeting sustained tubular p21 expression","volume":"13","author":"Al-Dabet","year":"2022","journal-title":"Nat Commun"},{"issue":"2","key":"2026041408013062700_bib23","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.3390\/ijms25021255","article-title":"Endothelial protein C receptor and 3K3A-activated protein C protect mice from allergic contact dermatitis in a contact hypersensitivity model","volume":"25","author":"Xue","year":"2024","journal-title":"Int J Mol Sci"},{"issue":"10","key":"2026041408013062700_bib24","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1084\/jem.20070404","article-title":"Endotoxemia and sepsis mortality reduction by non-anticoagulant activated protein C","volume":"204","author":"Kerschen","year":"2007","journal-title":"J Exp Med"},{"issue":"1","key":"2026041408013062700_bib25","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1111\/wrr.13148","article-title":"A recombinant signalling-selective activated protein C that lacks anticoagulant activity is efficacious and safe in cutaneous wound preclinical models","volume":"32","author":"Zhao","year":"2024","journal-title":"Wound Repair Regen"},{"issue":"12","key":"2026041408013062700_bib26","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1182\/blood-2014-09-599910","article-title":"Parmodulins inhibit thrombus formation without inducing endothelial injury caused by vorapaxar","volume":"125","author":"Aisiku","year":"2015","journal-title":"Blood"},{"issue":"5","key":"2026041408013062700_bib27","doi-asserted-by":"crossref","first-page":"E982","DOI":"10.1073\/pnas.1718600115","article-title":"PAR1 agonists stimulate APC-like endothelial cytoprotection and confer resistance to thromboinflammatory injury","volume":"115","author":"De Ceunynck","year":"2018","journal-title":"Proc Natl Acad Sci U A"},{"issue":"24","key":"2026041408013062700_bib28","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.1182\/blood-2017-05-782102","article-title":"Cytoprotective activated protein C averts Nlrp3 inflammasome-induced ischemia-reperfusion injury via mTORC1 inhibition","volume":"130","author":"Nazir","year":"2017","journal-title":"Blood"},{"issue":"11","key":"2026041408013062700_bib29","doi-asserted-by":"crossref","first-page":"3191","DOI":"10.1016\/j.jtha.2024.07.017","article-title":"Hepatocyte-independent PAR1-biased signaling controls liver pathology in experimental obesity","volume":"22","author":"Cline","year":"2024","journal-title":"J Thromb Haemost"},{"issue":"3","key":"2026041408013062700_bib30","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1021\/ml2002696","article-title":"Discovery of 1,3-diaminobenzenes as selective inhibitors of platelet activation at the PAR1 receptor","volume":"3","author":"Dockendorff","year":"2012","journal-title":"ACS Med Chem Lett"},{"issue":"17","key":"2026041408013062700_bib31","doi-asserted-by":"crossref","first-page":"3788","DOI":"10.1016\/j.bmc.2019.06.043","article-title":"The parmodulin NRD-21 is an allosteric inhibitor of PAR1 Gq signaling with improved anti-inflammatory activity and stability","volume":"27","author":"Gandhi","year":"2019","journal-title":"Bioorg Med Chem"},{"issue":"15","key":"2026041408013062700_bib32","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1182\/blood.2022017074","article-title":"Factor XII contributes to thrombotic complications and vaso-occlusion in sickle cell disease","volume":"141","author":"Sparkenbaugh","year":"2023","journal-title":"Blood"},{"issue":"11","key":"2026041408013062700_bib33","doi-asserted-by":"crossref","first-page":"4809","DOI":"10.1172\/JCI64578","article-title":"Extracellular hemin crisis triggers acute chest syndrome in sickle mice","volume":"123","author":"Ghosh","year":"2013","journal-title":"J Clin Invest"},{"issue":"15","key":"2026041408013062700_bib35","doi-asserted-by":"crossref","first-page":"4125","DOI":"10.1182\/blood-2010-08-301366","article-title":"Mechanisms of enhanced thrombus formation in cerebral microvessels of mice expressing hemoglobin-S","volume":"117","author":"Gavins","year":"2011","journal-title":"Blood"},{"issue":"5","key":"2026041408013062700_bib36","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1182\/blood.2023023528","article-title":"Heme-induced loss of renovascular endothelial protein C receptor promotes chronic kidney disease in sickle mice","volume":"144","author":"Chen","year":"2024","journal-title":"Blood"},{"key":"2026041408013062700_bib37","doi-asserted-by":"publisher","DOI":"10.1101\/2023.10.12.562109","article-title":"Liver size is predetermined in the neonate by adding lobules at the periphery","author":"Azizoglu","year":"14  2023","journal-title":"bioRxiv"},{"issue":"9","key":"2026041408013062700_bib38","doi-asserted-by":"crossref","first-page":"2514","DOI":"10.1016\/j.bmc.2018.04.016","article-title":"Characterization of protease-activated receptor (PAR) ligands: parmodulins are reversible allosteric inhibitors of PAR1-driven calcium mobilization in endothelial cells","volume":"26","author":"Gandhi","year":"2018","journal-title":"Bioorg Med Chem"},{"issue":"19","key":"2026041408013062700_bib39","doi-asserted-by":"crossref","first-page":"2676","DOI":"10.1182\/blood.2020009779","article-title":"P-selectin deficiency promotes liver senescence in sickle cell disease mice","volume":"137","author":"Vats","year":"2021","journal-title":"Blood"},{"issue":"2","key":"2026041408013062700_bib40","doi-asserted-by":"crossref","first-page":"C494","DOI":"10.1152\/ajpcell.00175.2022","article-title":"Molecular mechanisms of hepatic dysfunction in sickle cell disease: lessons from Townes mouse model","volume":"323","author":"Pradhan-Sundd","year":"2022","journal-title":"Am J Physiol Cell Physiol"},{"issue":"3","key":"2026041408013062700_bib41","first-page":"725","article-title":"Targeting P-selectin and interleukin-1\u03b2 in mice with sickle cell disease: effects on vaso-occlusion, liver injury and organ iron deposition","volume":"110","author":"Gotardo","year":"2025","journal-title":"Haematologica"},{"issue":"5","key":"2026041408013062700_bib42","first-page":"1535","article-title":"Impaired hemoglobin clearance by sinusoidal endothelium promotes vaso-occlusion and liver injury in sickle cell disease","volume":"109","author":"Kaminski","year":"2024","journal-title":"Haematologica"},{"issue":"8","key":"2026041408013062700_bib43","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1681\/ASN.2016070711","article-title":"Long-term endothelin-A receptor antagonism provides robust renal protection in humanized sickle cell disease mice","volume":"28","author":"Kasztan","year":"2017","journal-title":"J Am Soc Nephrol"},{"issue":"9","key":"2026041408013062700_bib44","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1111\/jth.14972","article-title":"High molecular weight kininogen contributes to early mortality and kidney dysfunction in a mouse model of sickle cell disease","volume":"18","author":"Sparkenbaugh","year":"2020","journal-title":"J Thromb Haemost"},{"issue":"1","key":"2026041408013062700_bib45","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/jth.14616","article-title":"Effects of vorapaxar on clot characteristics, coagulation, inflammation, and platelet and endothelial function in patients treated with mono-and dual-antiplatelet therapy","volume":"18","author":"Bliden","year":"2020","journal-title":"J Thromb Haemost"},{"issue":"20","key":"2026041408013062700_bib46","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1161\/CIRCULATIONAHA.114.015042","article-title":"Efficacy and safety of vorapaxar with and without a thienopyridine for secondary prevention in patients with previous myocardial infarction and no history of stroke or transient ischemic attack: results from TRA 2\u00b0P-TIMI 50","volume":"132","author":"Bohula","year":"2015","journal-title":"Circulation"},{"issue":"2","key":"2026041408013062700_bib47","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1007\/s00277-025-06216-1","article-title":"A review on disease modifying pharmacologic therapies for sickle cell disease","volume":"104","author":"Mahadevia","year":"2025","journal-title":"Ann Hematol"},{"issue":"4","key":"2026041408013062700_bib48","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1182\/bloodadvances.2024013693","article-title":"Is allogeneic transplantation for sickle cell disease still relevant in the era of gene therapy?","volume":"9","author":"Jones","year":"2025","journal-title":"Blood Adv"},{"issue":"14","key":"2026041408013062700_bib49","doi-asserted-by":"crossref","first-page":"3629","DOI":"10.1182\/bloodadvances.2023012477","article-title":"Costs and impact of disease in adults with sickle cell disease: a pilot study","volume":"8","author":"Lanzkron","year":"2024","journal-title":"Blood Adv"},{"issue":"3","key":"2026041408013062700_bib50","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1182\/blood-2012-04-424143","article-title":"Tissue factor promotes activation of coagulation and inflammation in a mouse model of sickle cell disease","volume":"120","author":"Chantrathammachart","year":"2012","journal-title":"Blood"},{"issue":"10","key":"2026041408013062700_bib51","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1182\/blood-2015-11-681114","article-title":"Thrombin-independent contribution of tissue factor to inflammation and cardiac hypertrophy in a mouse model of sickle cell disease","volume":"127","author":"Sparkenbaugh","year":"2016","journal-title":"Blood"},{"issue":"11","key":"2026041408013062700_bib52","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1182\/blood-2013-08-523936","article-title":"Differential contribution of FXa and thrombin to vascular inflammation in a mouse model of sickle cell disease","volume":"123","author":"Sparkenbaugh","year":"2014","journal-title":"Blood"},{"issue":"42","key":"2026041408013062700_bib53","doi-asserted-by":"crossref","first-page":"7479","DOI":"10.2174\/1381612819666131230131454","article-title":"Phase 1 safety, tolerability and pharmacokinetics of 3K3A-APC in healthy adult volunteers","volume":"19","author":"Lyden","year":"2013","journal-title":"Curr Pharm Des"},{"issue":"10","key":"2026041408013062700_bib54","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.exphem.2016.06.252","article-title":"Targeting Mac-1-mediated leukocyte-RBC interactions uncouples the benefits for acute vaso-occlusion and chronic organ damage","volume":"44","author":"Chen","year":"2016","journal-title":"Exp Hematol"},{"issue":"24","key":"2026041408013062700_bib55","doi-asserted-by":"crossref","first-page":"3818","DOI":"10.1182\/blood-2013-10-529982","article-title":"Heme-induced neutrophil extracellular traps contribute to the pathogenesis of sickle cell disease","volume":"123","author":"Chen","year":"2014","journal-title":"Blood"},{"issue":"2","key":"2026041408013062700_bib56","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1161\/CIRCRESAHA.121.319044","article-title":"Activated protein C strengthens cardiac tolerance to ischemic insults in aging","volume":"130","author":"Ren","year":"2022","journal-title":"Circ Res"},{"issue":"6","key":"2026041408013062700_bib57","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1111\/jth.13315","article-title":"Renal endothelial protein C receptor expression and shedding during diabetic nephropathy","volume":"14","author":"Lattenist","year":"2016","journal-title":"J Thromb Haemost"},{"issue":"5","key":"2026041408013062700_bib58","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1111\/j.1538-7836.2007.02480.x","article-title":"Proteolysis of the endothelial cell protein C receptor by neutrophil proteinase 3","volume":"5","author":"Villegas-Mendez","year":"2007","journal-title":"J Thromb Haemost"},{"issue":"11","key":"2026041408013062700_bib59","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.1021\/jm800180e","article-title":"Discovery of a novel, orally active himbacine-based thrombin receptor antagonist (SCH 530348) with potent antiplatelet activity","volume":"51","author":"Chackalamannil","year":"2008","journal-title":"J Med Chem"},{"key":"2026041408013062700_bib60","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.ejphar.2015.05.046","article-title":"In vitro pharmacological characterization of vorapaxar, a novel platelet thrombin receptor antagonist","volume":"762","author":"Hawes","year":"2015","journal-title":"Eur J Pharmacol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/7\/2351\/2511861\/blooda_adv-2025-017522-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/7\/2351\/2511861\/blooda_adv-2025-017522-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T12:01:42Z","timestamp":1776168102000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/7\/2351\/566398\/Targeting-PAR1-biased-signaling-with-parmodulin"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,31]]},"references-count":60,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,4,14]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025017522","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,4,14]]},"published":{"date-parts":[[2026,3,31]]}}}